Abstract: A shock mount includes four guide bolts and two rectangular guide assemblies to control motion. The guide bolts are fixed to a bottom portion and nuts are threaded onto the guide bolts to limit vertical travel of a sprung portion of the shock mount. The rectangular guide assemblies include a vertical guide plates separated from a bracing plate by a rubber sleeve to guide vertical movement of the sprung portion. One embodiment includes a horizontally offset support plate attachable to machinery.

Abstract: A filter tool for a wellbore may include an outer housing, a filtration system, at least one filter tool sensor, and a filter motor. The outer housing may have an interior wall comprising at least one port and an exterior wall defining an exterior surface of the filter tool. The exterior wall may be movable between a first position in which the exterior wall covers the at least one port in the interior wall and a second position in which the exterior wall uncovers the at least one port in the interior wall. The interior wall of the outer housing and the filtration system may cooperate to define a collection chamber. The filter motor may move the exterior wall of the outer housing between the first position and the second position. Embodiments also include systems and methods employing the filter tool.

Abstract: The present invention is directed to benzazepin-1,7-diol-derived compounds (I) for use in the diagnosis of NMDA (N-methyl-D-aspartate) receptor-associated diseases or disorders by positron emission tomography (PET), single-photon emission computed tomography (SPECT), liquid based-scintillation- and/or autoradiography-based assays. The invention also relates to a method for the diagnosis of NMDA receptor-associated diseases or disorders by administering to a patient or a sample of a patient in need of such diagnosis a compound of the invention in an amount effective for PET imaging, SPECT imaging, liquid based-scintillation- and/or autoradiography-based assays of NMDA receptors, recording at least one PET or SPECT scan, liquid based-scintillation or autoradiography result, and diagnosing an NMDA receptor-associated disease or disorder from an abnormal NMDA receptor expression pattern on the PET or SPECT scan, in the liquid based-scintillation or autoradiography result.

Abstract: The present invention relates to a compound of formula (I) wherein R1, R2, and R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a radiolabeled ligand.

Abstract: The present invention relates to a compound of formula (I) wherein R1 is defined as in the description and in the claims. The compound of formula (I) can be used as radiolabeled ligand.

Abstract: The present invention is directed to benzazepin-1-ol-derived compounds for use in the diagnosis of NMDA receptor-associated diseases or disorders by positron emission tomography (PET). The invention also relates to a method for the diagnosis of NMDA-receptor-associated diseases or disorders by administering to a patient in need of such diagnosis a radioactively labelled compound of the invention in an amount effective for PET imaging of NMDA receptors, recording at least one PET scan, and diagnosing an NMDA-receptor-associated disease or disorder from an abnormal NMDA receptor expression pattern on the PET scan. NMDA-receptor-associated diseases or disorders that can be diagnosed with the radioactively labelled benzazepin-1-ol-derived compounds include but are not limited to neurodegenerative diseases or disorders, Alzheimer's disease, depressive disorders, Parkinson's disease, traumatic brain injury, stroke, migraine, alcohol withdrawal and chronic and neuropathic pain.

Abstract: The present invention relates to a compound of formula (I) wherein R1 is defined as in the description and in the claims. The compound of formula (I) can be used as radiolabeled ligand.